RBC Capital analyst Stephen Hagan lowered his price target on Henry Schein to $62 and kept his Sector Perform rating after its Q4 results. The analyst notes that dental sales growth of 2.5% missed expectations relative to the 4.5% 3-year average and its FY19 earnings guidance came in well below consensus as well. Hagan further states that the company’s outlook is also raising concerns about its long-term growth prospects, with added pressure coming from higher 2019 business separation costs weighing further on the company’s margins.
https://thefly.com/landingPageNews.php?id=2867875
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.